-
Erleada Combo Shows Comparable Quality of Life Outcomes in Prostate Cancer
06 Feb 2025 03:16 GMT
… patients with advanced castration-sensitive prostate cancer, health-related quality of life … Zytiga (abiraterone acetate) and Deltasone (prednisone) (AAP), compared with those … Pathway Inhibitor Therapy for Advanced Prostate Cancer: Secondary Analysis of a …
-
Survival Outcomes of Apalutamide as a Starting Treatment: Impact in Real-World Patients with Metastatic Hormone Sensitive Prostate Cancer (OASIS) - Beyond the Abstract
01 Feb 2025 00:46 GMT
Treating Prostate Cancer
Metastatic castration-sensitive prostate cancer (mCSPC) … with metastatic prostate cancer were not … plus prednisone in metastatic, castration-sensitive prostate cancer. N … metastatic castration-sensitive prostate cancer: Final survival …
-
Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer: Secondary Analysis of a Randomized Clinical Trial.
14 Jan 2025 11:24 GMT
… -sensitive prostate cancer (CSPC): androgen deprivation therapy (ADT) plus abiraterone acetate and prednisone …
-
Assessing the impact of gozetotide in PSMA-positive prostate cancer
22 Dec 2024 06:45 GMT
… with metastatic, castration-resistant prostate cancer over individualized treatment without determination … abiraterone in combination with prednisone or prednisolone, enzalutamide or … for whom abiraterone (with prednisone or prednisolone), enzalutamide or …
-
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.
05 Feb 2025 12:38 GMT
… men with metastatic castration-resistant prostate cancer (mCRPC) with PTEN loss on … (1000 mg once daily) and prednisone (5 mg twice daily). OS …
-
Truqap Combination Shines in Phase III Trial for Prostate Cancer
26 Nov 2024 22:26 GMT
… aggressive form of prostate cancer with tumor … combination with abiraterone-prednisone and androgen deprivation … metastatic hormone-sensitive prostate cancer. By targeting a … metastatic hormone-sensitive prostate cancer demonstrated statistically significant …
-
AstraZeneca claims phase 3 success with combination therapy for prostate cancer
26 Nov 2024 15:12 GMT
… de novo metastatic hormone-sensitive prostate cancer (mHSPC). The combination therapy … in combination with abiraterone-prednisone and androgen deprivation therapy … PTEN-deficient metastatic hormone-sensitive prostate cancer,” said Susan Galbraith, Executive …
-
TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
25 Nov 2024 12:15 GMT
… with abiraterone-prednisone and androgen … products.
Notes
Prostate cancer
Prostate cancer is the second … castration-sensitive prostate cancer (mCSPC), prostate cancer cells need … Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. Target …
-
Prostate cancer: Three drug trials to watch
19 Nov 2024 11:21 GMT
… , given with prednisone, versus abiraterone acetate and prednisone for the treatment … gene-mutated metastatic castration-sensitive prostate cancer (mCSPC). The primary completion … with the combination Akeega plus prednisone saw a statistically significant …
-
Tumor regression after neoadjuvant hormonal therapy in high risk prostate cancer: pathological outcomes from a randomized phase II trial.
13 Nov 2024 11:46 GMT
High-risk localized prostate cancer (HRLPC) commonly progresses to metastatic … (1000 mg/d) plus prednisone (5 mg/d), with …
About
© 1995-2025